<DOC>
	<DOCNO>NCT00254657</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness levetiracetam reduce pain fibromyalgia compare placebo . Levetiracetam , anti-seizure drug , currently FDA-approved market use patient seizure . Levetiracetam may relieve pain reduce abnormal activity nervous system . A placebo inactive substance .</brief_summary>
	<brief_title>Levetiracetam Treatment Pain Associated With Fibromyalgia</brief_title>
	<detailed_description>The UCSF Pain Clinical Research Center ( PCRC ) conduct investigator-initiated 9-week , randomize , double-blind , placebo-controlled , parallel group study Levetiracetam . There total 6 study visit . Visit 1 screen visit ass subject eligibility , follow one-week period baseline daily pain sleep assessment . Visit 2 ( one week Visit 1 ) subject randomize 3/2-randomization scheme administer study medication . Subjects randomized treatment group start Levetiracetam 1 tablet 500/mg/day , titrate 500mg week maximum dose 3000 mg/day . Visits 3 , 4 , 5 , 6 ( occur 2 , 4 , 6 8 week start study drug ) include safety efficacy assessment . Study drug taper initiate Visit 6 .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1 . Male female 18 year age old . 2 . Subjects must meet 1990 American College Rheumatology Criteria diagnosis Fibromyalgia Syndrome . 3 . Subjects screen must average score least 40mm Visual Analog Scale ( VAS ) SFMcGill Pain Questionnaire ; baseline must average score least 4/10 last 7 day Daily Pain Rating Scale . 4 . Subjects must complete least 4 diary 7 day prior randomization . 5 . Subjects must discontinue use steroid , muscle relaxant , anticonvulsant , sodium channel blocker , topical analgesic , needlebased therapy , include trigger point injection acupuncture , least 1 week prior start study medication agree stay therapy throughout study . Continuation nonsteroidal antiinflammatories , antidepressant opiates allow , provide reach stable dose prior study entry maintain stable dose throughout study . 6 . Ability understand follow instruction investigator , include completion study diary describe protocol . 7 . Ability provide inform write consent . 1 . Subjects demonstrate hypersensitivity levetiracetam previously treat . 2 . Subjects severe liver kidney insufficiency ( AST , ALT , BUN , Creatinine twice upper limit reference range ) . 3 . Abnormal Westergen erythrocyte sedimentation rate ( e.g . ESR &gt; 40 mm/min ) 4 . Abnormal antinuclear antibody ( ANAâ‰¥1:160 ) , rheumatoid factor ( RF &gt; 80 IU/ml ) 5 . Subjects significant hematological disease , clot disorder . 6 . Subjects undergone trigger point injection needlebased therapy two week prior dose . 7 . Subjects severe pain may confound assessment pain due fibromyalgia . 8 . Subjects take take experimental drug , drug approve United States , participate participate clinical study 2 month prior clinical trial . 9 . Subjects history illicit drug alcohol abuse within last year . 10 . Pregnant lactating woman . 11 . Subjects consider unreliable medication compliance adherence schedule appointment determine investigator 12 . Subjects serious unstable medical psychological condition opinion investigator ( ) , would compromise subject 's participation study . 13 . Subjects involve unsettled litigation automobile accident , civil lawsuit , worker 's compensation pertaining fibromyalgia , current involvement outofcourt settlement litigation pertinent fibromyalgia , currently receive monetary compensation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Fibro</keyword>
	<keyword>Keppra</keyword>
	<keyword>Levetiracetam</keyword>
</DOC>